Is Iovance Biotherapeutics (IOVA) the Most Promising Penny Stock According to Analysts?
From Yahoo Finance: 2025-04-18 17:44:00
- Solus’ Dan Greenhaus and Invesco’s Brian Levitt discussed tariffs and market uncertainty on CNBC. Greenhaus believes worst-case scenarios are priced in, with Trump’s recent actions contributing to market rebound. Levitt warns of downside risks due to White House decisions, advocating for seizing long-term investment opportunities during uncertainty.
- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a biopharmaceutical company focusing on cell therapies for cancer treatment, specifically metastatic melanoma. Amtagvi, their FDA-approved TIL cell therapy, generated significant revenue in 2024. Analysts are optimistic about IOVA’s growth potential, ranking it as the 2nd most promising penny stock.
- In Q1 2024, Iovance Biotherapeutics (NASDAQ:IOVA) performed well, with Artisan Small Cap Fund adding to its position after FDA approval of Amtagvi. IOVA ranks second on the list of promising penny stocks. Despite IOVA’s growth potential, AI stocks are seen as having greater promise for high returns within a shorter timeframe.
Read more at Yahoo Finance: Is Iovance Biotherapeutics (IOVA) the Most Promising Penny Stock According to Analysts?